Treatments:
In total, 66 (70.6%) of 93 hospitalized CAP patients received intravenous sulbactam ampicillin (SAM). Of these patients, 24 (25.8%) were treated with simultaneous peroral macrolide. Further, of 18 CCAP patients, 16 (88.8%) received intravenous vancomycin and cefotaxime; 6 (33.3%), clindamycin; and 3 (16.66%), peroral macrolide. Three (3.22%) CAP patients underwent CT scan in addition to thoracic USG due to fever lasting >3 days and clinical deterioration. Then, treatment was modified in CCAP patients. The initial treatment protocols significantly differed between the two groups (p<0.001) (Table-4).